Company SpringWorks Therapeutics, Inc.

SWTX

US85205L1070

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 15:56:44 18/06/2025 BST			5-day change	1st Jan Change
46.87 ^USD	+0.02%		+0.26%	+29.73%

05-23	SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN	CI
05-23	Springworks Therapeutics Says Mirdametinib Recommended by EU Panel for Treating Plexiform Neurofibromas	MT

Business description: SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. OGSIVEO (nirogacestat) is the Company's Food and Drug Administration (FDA)-approved therapy. OGSIVEO (nirogacestat) is approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. The Company also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. Its ongoing developments include Nirogacestat for treatment of ovarian granulosa cell tumors, Nirogacestat in combination with B-cell maturation antigen (BCMA)-targeted agents, Mirdametinib Phase 2b ReNeu trial in NF1-PN and Brimarafenib (BGB-3245). The Company's early-stage pipeline includes SW-682, an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluated in Hippo-mutant solid tumors.

Number of employees: 368

Sales by Activity: SpringWorks Therapeutics, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
Developing and Commercializing Life-Changing Medicines	35M	-	-	5.45M	192M

See all business segments

Geographical breakdown of sales: SpringWorks Therapeutics, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
United States	35M	-	-	5.45M	192M

See all geographic segments

Executive Committee: SpringWorks Therapeutics, Inc.

Manager	Title	Age	Since
Saqib Islam CEO	Chief Executive Officer	55	31/07/2018
Frank Perier DFI	Director of Finance/CFO	65	31/07/2019
Tai-An Lin CTO	Chief Tech/Sci/R&D Officer	62	10/09/2023
James Cassidy CTO	Chief Tech/Sci/R&D Officer	66	31/07/2021
Badreddin Edris COO	Chief Operating Officer	38	31/12/2020

See SPRINGWORKS THERAPEUTICS, INC. governance

Composition of the Board of Directors: SpringWorks Therapeutics, Inc.

Director	Title	Age	Since
Daniel Lynch CHM	Chairman	66	31/07/2017
Freda Lewis-Hall BRD	Director/Board Member	70	31/07/2017
Saqib Islam BRD	Director/Board Member	55	31/07/2018
Alan Fuhrman BRD	Director/Board Member	68	31/07/2019
Julie Hambleton BRD	Director/Board Member	67	19/05/2020
Carlos Alban BRD	Director/Board Member	62	13/07/2022
Martin MacKay BRD	Director/Board Member	68	28/07/2024

Composition of the Board of Directors

Shareholders: SpringWorks Therapeutics, Inc.

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 14.95 %	11,204,799	14.95 %	523 M $
Vanguard Fiduciary Trust Co. 9.452 %	7,082,581	9.452 %	331 M $
BlackRock Advisors LLC 7.848 %	5,880,889	7.848 %	275 M $
STATE STREET CORPORATION 3.892 %	2,916,341	3.892 %	136 M $
T. Rowe Price International Ltd. 3.447 %	2,582,732	3.447 %	121 M $

List of SPRINGWORKS THERAPEUTICS, INC. shareholders

Company details: SpringWorks Therapeutics, Inc.

Springworks Therapeutics, Inc.

100 Washington Boulevard

06902, Stamford

http://www.springworkstx.com

address SpringWorks Therapeutics, Inc.(SWTX)

Biopharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SPRINGWORKS THERAPEUTICS, INC.	+0.02%	+0.26%	+29.44%	+101.33%	3.53B
CSL LIMITED	+1.12%	-0.88%	-16.22%	-5.48%	75.35B
SAMSUNG BIOLOGICS CO.,LTD.	-0.39%	+1.50%	+37.72%	+28.48%	52.44B
UCB	-1.23%	-2.65%	+13.88%	+98.49%	34.64B
BIOGEN INC.	+0.71%	-4.21%	-43.01%	-38.39%	18.54B
INNOVENT BIOLOGICS, INC.	+1.95%	-0.51%	+106.57%	+207.63%	16.22B
ALTEOGEN INC.	+5.19%	+10.04%	+53.02%	+952.11%	15.5B
INTRA-CELLULAR THERAPIES, INC.	-0.04%	-.--%	+91.48%	+140.03%	14.02B
INCYTE CORPORATION	+0.70%	+0.84%	+13.00%	-5.07%	13.32B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-1.93%	-6.90%	-5.74%	-41.10%	11.29B
Average	+0.61%	-1.59%	+28.02%	+143.80%	25.49B
Weighted average by Cap.	+0.52%	-2.06%	+17.60%	+92.96%